Trial
NCT02448810
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Baxalta now part of Shire
Collaborators
—
Condition
Metastatic Colorectal Cancer
Intervention
BAX69 + infusional 5-FU/LV
Why stopped
Based on overall benefit-risk assessment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-25